Skip to main content
Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.199
+0.009 (4.74%)
Apr 28, 2026, 3:59 PM EST

Northwest Biotherapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-60.16-83.78-62.6-105.03179.13
Upgrade
Depreciation & Amortization
2.342.041.731.50.59
Upgrade
Other Amortization
1.892.482.372.772.3
Upgrade
Stock-Based Compensation
1.213.464.4112.315.5
Upgrade
Other Operating Activities
-38.784.1428.48-238.54
Upgrade
Change in Accounts Payable
13.699.85-4.436.85-0.6
Upgrade
Change in Other Net Operating Assets
-0.730.160.730.363.32
Upgrade
Operating Cash Flow
-44.76-57.02-53.64-52.78-38.3
Upgrade
Capital Expenditures
-1.5-1.01-3.44-2.9-6.02
Upgrade
Investing Cash Flow
-1.82-1.01-3.44-2.9-6.02
Upgrade
Short-Term Debt Issued
-0.20.012.570.25
Upgrade
Long-Term Debt Issued
31.2634.0233.345.629.67
Upgrade
Total Debt Issued
31.2634.2233.358.1729.92
Upgrade
Long-Term Debt Repaid
-1.27-1.43-0.39-5.49-5.83
Upgrade
Total Debt Repaid
-1.27-1.43-0.39-5.49-5.83
Upgrade
Net Debt Issued (Repaid)
29.9932.7832.962.6824.09
Upgrade
Issuance of Common Stock
19.3415.751.7220.5724.05
Upgrade
Other Financing Activities
-0.054.75--
Upgrade
Financing Cash Flow
49.3356.7952.7641.9748.13
Upgrade
Foreign Exchange Rate Adjustments
-1.881.3-0.525.511.37
Upgrade
Net Cash Flow
0.870.05-4.84-8.25.19
Upgrade
Free Cash Flow
-46.27-58.03-57.07-55.68-44.31
Upgrade
Free Cash Flow Margin
-3357.55%-4199.06%-2954.14%-3308.20%-4409.35%
Upgrade
Free Cash Flow Per Share
-0.03-0.05-0.05-0.06-0.04
Upgrade
Cash Interest Paid
0.390.130.060.911.73
Upgrade
Levered Free Cash Flow
-23.95-30.19-118.13-44.98-270
Upgrade
Unlevered Free Cash Flow
-20.4-27.81-117.23-43.96-269.17
Upgrade
Change in Working Capital
12.9610-3.77.212.73
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.